VAERS Explorer
Back to explore

Report #2867724

Received Oct 23, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
Age unknown
State
—
Recovered
Not recovered
Vaccinated
Jun 14, 2024
Onset
Oct 25, 2024
Days to onset
133
Hospital days
—

Vaccines (2)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS2UNK—
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS1UNK—

Symptoms (2)

PsoriasisPustule

Symptom narrative

Psoriasis; This non-serious case was reported by a consumer and described the occurrence of psoriasis in a 68-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included inflammatory bowel disease (dermatologist recommended massive amount of probiotics to heal ongoing IBD). Concomitant products included tamsulosin hydrochloride (Tamsulosine), dicycloverine hydrochloride (Dicyclomine) and famotidine (Famot). On 18-AUG-2024, the patient received the 2nd dose of Shingrix. On 14-JUN-2024, the patient received the 1st dose of Shingrix. On 25-OCT-2024, 68 days after receiving Shingrix and 133 days after receiving Shingrix, the patient experienced psoriasis (Verbatim: Psoriasis). The outcome of the psoriasis was not resolved. It was unknown if the reporter considered the psoriasis to be related to Shingrix and Shingrix. It was unknown if the company considered the psoriasis to be related to Shingrix and Shingrix. Additional Information: GSK Receipt Date: 01-OCT-2025 The patient experienced psoriasis breakouts that began as small pimples, filled with pus, and eventually burst, leaving open sores that took a long time to heal. These breakouts appeared across the body. The patient reported this adverse reaction to the vaccine reporting agency but had not been contacted by anyone at the time of reporting and expressed a need for assistance. The symptoms were treated. The patient's dermatologist had recommended a high intake of probiotics to manage ongoing IBS-D. The patient completed the recommended three-month course and voluntarily extended it for an additional three months, entering the fourth month of treatment. Permission to contact the patient was granted. The batch number was not provided, and we are unable to contact the reporter.

Current illness

Inflammatory bowel disease (dermatologist recommended massive amount of probiotics to heal ongoing IBD)

Other medications

TAMSULOSINE; DICYCLOMINE; FAMOT